Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 175

1.

Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination.

Koya T, Date I, Kawaguchi H, Watanabe A, Sakamoto T, Togi M, Kato T Jr, Yoshida K, Kojima S, Yanagisawa R, Koido S, Sugiyama H, Shimodaira S.

Pharmaceutics. 2020 Mar 28;12(4). pii: E305. doi: 10.3390/pharmaceutics12040305.

PMID:
32231023
2.

In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination.

Shimodaira S, Yanagisawa R, Koya T, Hirabayashi K, Higuchi Y, Sakamoto T, Togi M, Kato T Jr, Kobayashi T, Koizumi T, Koido S, Sugiyama H.

Vaccines (Basel). 2019 Sep 19;7(3). pii: E120. doi: 10.3390/vaccines7030120.

3.

Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer.

Yoshida S, Ito Z, Suka M, Bito T, Kan S, Akasu T, Saruta M, Okamoto M, Kitamura H, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Sugiyama H, Koido S.

Cancer Invest. 2019;37(9):463-477. doi: 10.1080/07357907.2019.1661427. Epub 2019 Sep 18.

PMID:
31490702
4.

Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.

Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H.

Medicine (Baltimore). 2019 Aug;98(33):e16771. doi: 10.1097/MD.0000000000016771.

5.

Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.

Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Yoshida S, Kajihara M, Hokari A, Saruta M, Yoshida N, Kobayashi M, Ohkusa T, Shimodaira S, Okamoto M, Sugiyama H, Koido S.

Oncology. 2019;97(3):135-148. doi: 10.1159/000500359. Epub 2019 Jun 19.

PMID:
31216557
6.

What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia.

Nakata J, Oji Y, Oka Y, Sugiyama H.

Expert Rev Hematol. 2019 Apr;12(4):211-213. doi: 10.1080/17474086.2019.1593824. Epub 2019 Mar 18. No abstract available.

PMID:
30882253
7.

Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.

Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegawa K, Hosen N, Tsuboi A, Oka Y, Kumanogoh A, Oji Y, Sugiyama H.

Oncotarget. 2018 Nov 13;9(89):36029-36038. doi: 10.18632/oncotarget.26338. eCollection 2018 Nov 13.

8.

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.

Campillo-Davo D, Fujiki F, Van den Bergh JMJ, De Reu H, Smits ELJM, Goossens H, Sugiyama H, Lion E, Berneman ZN, Van Tendeloo V.

Front Immunol. 2018 Nov 7;9:2503. doi: 10.3389/fimmu.2018.02503. eCollection 2018.

9.

A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H.

Cancer Immunol Immunother. 2019 Feb;68(2):331-340. doi: 10.1007/s00262-018-2274-1. Epub 2018 Nov 14.

10.

Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity.

Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, Aoyama N, Nishida Y, Tsuboi A, Oka Y, Nishida S, Nakata J, Hosen N, Oji Y, Sugiyama H.

Oncotarget. 2018 Sep 25;9(75):34132-34141. doi: 10.18632/oncotarget.26139. eCollection 2018 Sep 25.

11.

Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines.

Hanada S, Tsuruta T, Haraguchi K, Okamoto M, Sugiyama H, Koido S.

Hum Vaccin Immunother. 2019;15(2):397-406. doi: 10.1080/21645515.2018.1524238. Epub 2018 Oct 12.

12.

Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S.

Oncol Lett. 2018 Aug;16(2):2682-2692. doi: 10.3892/ol.2018.8961. Epub 2018 Jun 13.

13.

A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches.

Versteven M, Van den Bergh JMJ, Broos K, Fujiki F, Campillo-Davo D, De Reu H, Morimoto S, Lecocq Q, Keyaerts M, Berneman Z, Sugiyama H, Van Tendeloo VFI, Breckpot K, Lion E.

Oncotarget. 2018 Jun 12;9(45):27797-27808. doi: 10.18632/oncotarget.25591. eCollection 2018 Jun 12.

14.

Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors.

Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S.

Anticancer Res. 2018 Apr;38(4):2227-2234.

PMID:
29599343
15.

WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.

Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S.

Anticancer Res. 2018 Apr;38(4):2217-2225.

PMID:
29599342
16.

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.

Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Oba MS, Sato M, Morimoto S, Fujiki F, Eguchi H, Nagano H, Kumanogoh A, Unno M, Kon M, Shimada H, Ito K, Homma S, Oka Y, Morita S, Sugiyama H.

Cancer Immunol Res. 2018 Mar;6(3):320-331. doi: 10.1158/2326-6066.CIR-17-0386. Epub 2018 Jan 22.

17.

WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.

Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H.

Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21.

18.

The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M, Watanabe K, Yoshida M, Satoh K, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Manabe M, Ichihara H, Aoyama Y, Mugitani A, Nakao T, Hino M, Uchibori R, Ozawa K, Baba Y, Terakura S, Wada N, Morii E, Nishimura J, Takeda K, Oji Y, Sugiyama H, Takagi J, Kumanogoh A.

Nat Med. 2017 Dec;23(12):1436-1443. doi: 10.1038/nm.4431. Epub 2017 Nov 6.

PMID:
29106400
19.

Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.

Oka Y, Tsuboi A, Nakata J, Nishida S, Hosen N, Kumanogoh A, Oji Y, Sugiyama H.

Oncol Res Treat. 2017;40(11):682-690. doi: 10.1159/000481353. Epub 2017 Oct 18. Review.

20.

Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer.

Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H.

Discov Med. 2017 Aug;24(130):41-49. Review.

Supplemental Content

Loading ...
Support Center